[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 215
Citations 0
news@JAMA
February 5, 2014

From JAMA’s Daily News Site

JAMA. 2014;311(5):455. doi:10.1001/jama.2014.24

The first agent in a new class of drugs may offer some relief from the hallucinations and delusions of Parkinson disease psychosis.

Recent data show that pimavanserin, a selective serotonin 5-HT2A inverse agonist, provided significant antipsychotic benefit to 199 patients with Parkinson disease psychosis treated at 54 clinical trial sites in the United States and Canada. Patients randomly received 40 mg of pimavanserin or a placebo for 6 weeks. At day 43 of the study, an analysis showed that symptoms improved by 37% in patients who received pimavanserin compared with 14% in the placebo group.

First Page Preview View Large
First page PDF preview
First page PDF preview
×